anti-cd20 antibody is effective in the patient with refractory amegakaryocytic thrombocytopenia, 25 months follow up.

نویسندگان

mehrzad mirzania imam khomini hospital complex, vali-e-asr hospital, tehran university of medical sciences, tehran, iran.

sedigheh khalili arak university of medical sciences, arak, iran.

akbar hasanpoor arak university of medical sciences, arak, iran.

ahmad reza shamshiri hematology-oncology and stem cell research center, tehran university of medical sciences, tehran, iran.

چکیده

amegakaryocytic thrombocytopenia (amt) is a rare cause of acquired thrombocytopenia. the pathogenesis and treatment of amt is not clearly known. here we demonstrate a 50-year-old man presented with the clinical manifestations of severe thrombocytopenia (7000 platelets/µl) with a marked decrease to absent of megakaryocytes in the bone marrow. the patient did not respond to intravenous immunoglobulin, cyclosporine or high dose prednisone. after the treatment with anti-cd20 antibody (rituximab), the patient's clinical symptoms and platelet counts improved.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Anti-CD20 Antibody is Effective in the Patient with Refractory Amegakaryocytic Thrombocytopenia, 25 Months Follow up

Amegakaryocytic thrombocytopenia (AMT) is a rare cause of acquired thrombocytopenia. The pathogenesis and treatment of AMT is not clearly known. Here we demonstrate a 50-year-old man presented with the clinical manifestations of severe thrombocytopenia (7000 platelets/µl) with a marked decrease to absent of megakaryocytes in the bone marrow. The patient did not respond to intravenous immunoglob...

متن کامل

Anti-CD20 antibody treatment in refractory Class IV lupus nephritis.

1. Foley RN, Parfrey PS. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32 [Suppl 3]: S112–S119 2. Cozzolino M, Brancaccio D, Gallieni M, Slatopolsky E. Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 2005; 68: 429–436 3. Ketteler M, Bongartz P, Westenfeld R et al. Association of low fetuin-A (AHSG) concentrations in ...

متن کامل

The results of six months follow up in patients with subclinical thyrotoxicosis

Introduction: There is no definite treatment for subclinical hyperthyroidism which is defined as suppressed TSH and normal T3 and T4 levels. In this study, patients with subclinical hyperthyroidism were followed for 6 months without any medical treatment. Methods: A total number of 285 patients of individuals who participated in Tehran glucose and lipid study and had TSH≤0.3 mu/l and normal T...

متن کامل

Follow-Up Visits in Doctor-Patient Communication: The Vietnamese Case

In a “follow-up visit”, a patient seeks medical attention for an existing health problem. Using data from the Vietnamese public hospital system, we present a more nuanced analysis of follow-ups in health communication than the one currently available. To be specific, we discriminate between “same follow-ups”, in which the doctor is the same one as in the last visit, and “different follow-ups”, ...

متن کامل

autosomal recessive chronic granulomatous disease, iga deficiency and refractory autoimmune thrombocytopenia responding to anti-cd20 monoclonal antibody

immunodeficiency and autoimmune disease may occur concomitantly in the same individual. some of the immunodeficiency syndromes, especially humoral defects are associated with autoimmune disorders. hematological manifestations such as thrombocytopenia and hemolytic anemia are the most common presentations. persistent antigen stimulation due to an inherent defect in the ability of the immune syst...

متن کامل

Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab).

BACKGROUND Rituximab, a chimeric monoclonal anti-CD20 antibody, has recently been used for the treatment of refractory antibody mediated autoimmune diseases such as immune mediated thrombocytopenia and haemolytic anaemia. PATIENTS Because of its novel mechanism of action, rituximab was used to treat three patients with refractory systemic antibody mediated autoimmune disorders. The first pati...

متن کامل

منابع من

با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید


عنوان ژورنال:
international journal of hematology-oncology and stem cell research

جلد ۸، شماره ۲، صفحات ۴۱-۴۴

میزبانی شده توسط پلتفرم ابری doprax.com

copyright © 2015-2023